Impact of a Pregabalin Step Therapy Policy Among Medicare Advantage Beneficiaries

Pain Practice

Volumn 14, Issue 5, 2014, Pages 419-426

  Suehs, Brandon T ^a   Louder, Anthony ^a   Udall, Margarita ^b   Cappelleri, Joseph C ^b   Joshi, Ashish V ^b   Patel, Nick C ^a  

^a Research Scientist   (United States)

^b PFIZER INC   (United States)

Author keywords

Diabetic neuropathy, painful; Fibromyalgia; Formulary policy; Postherpetic neuralgia; Pregabalin

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; MUSCLE RELAXANT AGENT; OPIATE DERIVATIVE; PREGABALIN; PRESCRIPTION DRUG; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL PHARMACY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG COST; DRUG UTILIZATION; FEMALE; FIBROMYALGIA; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBSERVATIONAL STUDY; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PHARMACEUTICAL CARE; POSTHERPETIC NEURALGIA; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; DRUG USE; ECONOMICS; EPIDEMIOLOGY; PAIN; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALGESICS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEDICARE PART C; PAIN; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84901694661     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12073     Document Type: Article

References (15)

1. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7:297-302.
2. Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17:143-155.
3. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836.
4. Arnold L, Goldenberg D, Stanford S, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336.
5. Shoemaker SJ, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2011;16:S1-S21.
6. Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care. 2009;15:123.
7. Mark TL, Gibson TM, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry. 2010;167:1202-1209.
8. Bazalo G, Weiss RC, Joshi AV. Impact of a prior authorization for pregabalin on health plan drug expenditures. Am J Manag Care. 2010;16:154.
9. Margolis J, Johnston S, Chu B, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15:e95.
10. Margolis J, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16:447.
11. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41:761.
12. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care. 2006;12:110.
13. Kleinbaum DG, Klein M. Logistic Regression: A Self-Learning Text, 1st ed. New York, NY: Springer; 2010.
14. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS® for Mixed Models, 2nd ed. Cary, NC: SAS Institute; 2006.
15. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc. 1983;78:605-610.